Skip to main content
Go to homepage

Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma

Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma

Description:

For complete details, please view the study on clinicaltrials.gov.

Study in conjunction with Cincinnati Children's Hospital.

Interested in participating?
We are currently recruiting
Study Sponsor:

National Cancer Institute

Full IRB Study Title:
A Phase 1 and Phase II and Re-Treatment Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma
If you are interested in this study or have questions about your child's eligibility, please contact:
Rebecca D. Considine Research Institute, 330-543-3193 or email research@akronchildrens.org
Lead Investigator
Steven Kuerbitz, MD

Director, Divisional Research and Stem Cell Transplantation; Pediatric Hematologist-Oncologist
Showers Family Center for Childhood Cancer and Blood DisordersPediatric Stem Cell Transplant Program